Metaplanet surges over 12% on Bitcoin-backed yield product plans
Metaplanet, the Tokyo-listed company that has become Asia’s largest public Bitcoin treasury holder, saw its stock jump over 12% after announcing plans to acquire a securities firm and launch Bitcoin-backed yield products targeting Japanese investors.
The company is buying Siiibo Securities for 2.1 billion yen, roughly $13 million. The deal is expected to close in July 2026 and will grant Metaplanet something it has been chasing: a Type I securities license in Japan.
From Bitcoin hoarder to Bitcoin bank
Metaplanet has spent the last couple of years doing what MicroStrategy made famous: buying Bitcoin and putting it on the balance sheet. As of April 2026, Metaplanet holds approximately 40,177 BTC, acquired at an average cost basis of around $97,593 per coin.
Under what the company calls “Project Nova,” Metaplanet is pivoting from pure treasury accumulation to regulated product distribution. The acquisition of Siiibo Securities, which will be rebranded as Metaplanet Securities, is the infrastructure needed to make that happen. A Type I securities license in Japan allows a firm to deal in a wide range of securities products, and getting one from scratch is notoriously difficult and time-consuming.
Targeting Japan’s $7.4 trillion cash pile
Japanese households are sitting on an estimated $7.4 trillion in cash and savings. Metaplanet’s pitch is Bitcoin-backed products that target yields in the 6% to 12% range. The company already launched “Metaplanet Prefs” in 2025, a Bitcoin-backed investment vehicle designed specifically for this purpose.
CEO Simon Gerovich has been the architect of this strategy, steering the company toward becoming a full-stack Bitcoin financial services firm.
What this means for investors
The stock initially moved about 3.5% on the acquisition news before climbing higher. Metaplanet’s shares have been volatile throughout its Bitcoin transformation, with swings exceeding 12% during major announcements becoming something of a norm.
Metaplanet is currently the only major public company in Asia running this playbook. Japan’s largest financial institutions, from Nomura to SBI Holdings, have been steadily building their own crypto capabilities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
